FDA Accepts Supplement Application for Injectafer (Ferric Carboxymaltose)
The FDA has accepted the supplemental application for Injectafer (ferric carboxymaltose) submitted by AM REGENT.
Asset / Drug
Drug and asset intelligence for Injectafer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.